Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Andrew Dudum, a director, 10% owner and CEO-related reporting person of Hims & Hers Health, Inc. (HIMS), sold 65,110 shares of Class A common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted August 28, 2024. The sales generated an average weighted price of $50.5745 per share, with individual sale prices ranging from $50.06 to $50.94. After the reported transactions, the reporting person beneficially owned 95,315 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 09/19/2025 and includes an undertaking to provide share-by-share price details upon request.
Patrick Harrison Carroll, Chief Medical Officer and director of Hims & Hers Health, Inc. (HIMS), reported transactions dated 09/15/2025 on Form 4. He was granted 16,521 RSUs that convert one-for-one into Class A common stock and additional RSU awards listed in the filing totaling 16,521 + 8,148 + 4,840 + 3,533 units across entries. The issuer withheld 6,500 shares to satisfy tax withholding at a reported price of $53.96, reducing reported Class A common stock beneficial ownership from 186,461 to 179,961 following the withholding. The RSUs are subject to service-based vesting schedules, generally over four years with quarterly vesting dates specified in the filing.
The filing is a reporting of equity awards and related withholding; it documents grant mechanics, vesting schedules, and post-transaction beneficial ownership levels but does not provide compensation totals in dollars beyond the withholding price or other company financial metrics.
Hims & Hers Health, Inc. (HIMS) insider filing shows Chief Legal Officer Soleil Boughton reported RSU vesting and related withholding on 09/15/2025. The filing records 41,420 RSUs vested (reported as acquired) and 22,829 shares withheld by the issuer at $53.96 to satisfy tax obligations, leaving 169,041 shares beneficially owned after the transactions. Multiple classes of service-based RSUs vested or were reported as vested with specific quarterly vesting schedules; the filing explains these RSUs convert one-for-one into Class A common shares. The form is signed by an attorney-in-fact on behalf of the reporting person.
Insider transaction summary for HIMS: The Form 4 shows Irene Becklund had multiple equity events on 09/15/2025. Non-derivative entries report 17,983 shares added, resulting in 18,695 shares beneficially owned, and 8,867 shares withheld at a price of $53.96, leaving 9,828 shares after that withholding. Table II reports the vesting/settlement of several restricted stock unit grants, with individual RSU vesting amounts of 1,871, 4,019, 2,291, 4,065, 4,345, and 1,392 RSUs, and aggregate post-transaction share counts listed per line. The filing is signed by an attorney-in-fact on behalf of Ms. Becklund.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions on 09/15/2025 executed pursuant to a Rule 10b5-1 trading plan adopted March 4, 2025. The Form 4 shows option exercises and RSU vesting events, plus a sale and shares withheld for taxes. Reported activity includes option exercises at exercise prices of $11.53, $6.82 and $5.01, a sale of 4,150 Class A shares at $56 each, and withholding of 39,872 shares to cover tax obligations. The final line reports 310,888 shares of Class A common stock beneficially owned following the transactions. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions on Form 4 dated 09/15-09/16/2025. The filing shows vesting and settlement of Restricted Stock Units (RSUs) and exercises of stock options at an exercise price of $2.43, with contemporaneous sales of shares at weighted average prices in the low-$50s. Several share-withholdings covered tax obligations. The reporting person used a Rule 10b5-1 trading plan adopted August 28, 2024 to effect option exercises and subsequent share sales. The Form 4 also lists substantial indirect holdings held in various trusts.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple equity transactions dated 09/15/2025. The filing shows settlement/vesting of restricted stock units and the exercise of stock options, followed by share sales. The issuer withheld 58,021 shares to cover tax withholding on vested RSUs. The reporting person exercised 110,000 stock options at an exercise price of $5.01. Subsequent sales included 117,792 shares at a weighted average price of $55.2503 and 27,208 shares at a weighted average price of $55.7936. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.
Kare Schultz, a director of Hims & Hers Health, Inc. (HIMS), reported a grant of 6,623 restricted stock units (RSUs) on a Form 4 covering transactions dated 09/15/2025. The RSUs represent a contingent right to receive one share of Class A common stock per RSU and are subject to service-based vesting over three years with 1/3 vesting on 09/15/2025, 1/3 on 09/15/2026, and 1/3 on 09/15/2027. Following the reported transactions, the filing shows Schultz beneficially owns 15,741 shares of Class A common stock directly and 13,247 derivative securities (RSU-based) directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Hims & Hers Health, Inc. (HIMS) filing a Form 144 notifies the proposed sale of 65,110 Class A shares through Fidelity Brokerage Services on 09/17/2025 with an aggregate market value of $3,292,903.57. The shares were acquired by restricted stock vesting on 09/15/2025 and paid as compensation. The filing also lists multiple Class A sales by Andrew Dudum and the Dudum Family Trust during the past three months, including sizable single-month transactions on 07/21/2025, 08/18/2025 and 09/16/2025. The filer certifies they are not aware of any undisclosed material adverse information and provides broker details and seller addresses as required by Rule 144.
Hims & Hers Health, Inc. filing a Form 144 notifies the proposed sale of 2,637 Class A shares by a holder whose shares were acquired on 09/15/2025 through restricted stock vesting and paid as compensation. The filing lists the broker as Fidelity Brokerage Services LLC and an approximate sale date of 09/17/2025, with an aggregate market value of $133,168.50. The issuer's total Class A shares outstanding are stated as 217,641,958, indicating the proposed sale represents a very small fraction of outstanding stock. The filing also discloses six prior Class A sales by the same person between 06/17/2025 and 08/25/2025, each of roughly 2,571–2,572 shares with gross proceeds ranging from $114,486.63 to $153,677.00. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.